Affibody Ab

Johan Seijsing

Elin Gunneriusson

Malin Lindborg

Caroline Ekblad

Torbjörn Gräslund

Lars B Abrahmsen

John Löfblom

Fredrik Frejd

Lars Abrahmsén

Lindvi Gudmundsdotter

John Löblom

Lars Abrahmsen

Torbjorn Graslund

John Lofblom

Lars ABRAHMSÉN

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Polypeptides

The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Neonatal Fc receptor binding dimer and methods of use

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX(SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Growing community of inventors

Stockholm, Sweden

Johan Seijsing